Stockwinners Market Radar for October 30, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:46 EDT Pfizer says COVID vaccine EUA for kids 'supported by clinical data' - Pfizer (PFE) and BioNTech (BNTX) announced that the U.S. Food and Drug Administration has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age. For this age group, the vaccine is to be administered in a two-dose regimen of 10-microgram doses given 21 days apart. The 10-microgram dose level was carefully selected based on safety, tolerability and immunogenicity data. This is the first COVID-19 vaccine authorized in the U.S. for individuals 5 through 11 years of age. "This is a day so many parents, eager to protect their young children from this virus, have been waiting for," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "Over 6 million children in the U.S. have been diagnosed with COVID-19 since the start of this pandemic, and a high number of young people continue to be infected every week. With this FDA authorization, we have achieved another key marker in our ongoing effort to help protect families and communities, and to get this disease under control." "Today's emergency use authorization is supported by clinical data showing a favorable safety profile and high vaccine efficacy in children, underlining its potential to address a current public health need," said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. "As children 5 through 11 get reacclimated to the new school year, both in and out of the classroom, our goal is to help keep them safe and protected and get them back to normalcy."

17:14 EDT Northrop Grumman awarded $108.84M Air Force contract modification - Northrop Grumman has been awarded a not-to-exceed $108.84M bilateral modification to a previously awarded undefinitized contract action for RQ-4 Global Hawk aircraft sustainment. The modification provides for a second year of contractor logistics support services. Work will be performed in the Republic of Korea, and Sierra Vista, Arizona, and is expected to be completed by February 29, 2024. Foreign military sale funds in the amount of $22.89M are being obligated at the time of award, and the total cumulative face value of the contract is $267.23M. Air Force Life Cycle Management Center is the contracting activity.

17:12 EDT General Electric awarded $1.58B Air Force contract - General Electric has been awarded a $1.58B firm-fixed-price contract including all options for the F-15EX Lots 2+ propulsion system procurement. This contract provides for 29 F110-GE-129 engines for the F-15EX fleet. The contract also provides seven option lots for a most probable quantity of 329 total engines if all options are exercised. Work will be performed in Cincinnati, Ohio; and San Antonio, Texas, and is expected to be completed by June 30, 2031. This award is the result of a competitive source selection in which two offers were received. FY21 aircraft procurement funds in the amount of $136.56M will be obligated at the time of award. Air Force Life Cycle Management Center is the contracting activity. There is known congressional interest pertaining to this acquisition.

16:37 EDT Meta acquires VR startup Within, terms not disclosed - Meta (MVRS), the new name for Facebook (FB), is acquiring VR experience startup Within, which is behind VR fitness service "Supernatural." "Virtual reality and the metaverse bring us all the opportunity to connect and share experiences in meaningful and magical ways," said Jason Rubin, VP of Play at Oculus. "Thousands of people have already used the power of virtual reality to build fitness routines with Supernatural, an immersive VR fitness service that aims to make your daily workout the highlight of your day. Look no further than Supernatural's own Facebook Group where 20K+ members are supporting each other on a daily basis as they celebrate the newfound joy, acceptance, and fun that many say Supernatural and Quest have enabled in their lives. Like us, Supernatural, and their creators at Within, believe deeply in the power of the metaverse and VR to bring people together and empower positive change. Today, I'm happy to announce that Within (along with Supernatural) have entered into an agreement to join Meta. Supernatural will continue to be operated independently as part of Reality Labs, and will continue to create fitness, wellness, and social experiences in VR, helping people achieve their goals in the most joyful and connected way possible. We're eager to help Within continue bringing joy, awe, and wonder to the Supernatural community, with more music, creative ways to workout, features, and social experiences. Together we will also explore ways we can enhance future hardware to support VR fitness apps, encouraging other developers to bring new fitness experiences to VR. We believe fitness will be a massive success in VR where multiple third-party fitness apps can succeed." This transaction will be subject to customary closing conditions and regulatory approval. Financial terms of the deal were not disclosed.

16:31 EDT ObsEva announces departure of CFO David Renas - ObsEva SA announced that current Chief Financial Officer David Renas will be stepping down from his position for personal reasons, effective January 5, 2022. ObsEva has retained an executive search firm to assist the company's board with identifying a new Chief Financial Officer.

16:16 EDT Taitron raises quarterly dividend 12.5% to 4.5c per share - Payable on November 30 to stockholders of record as of the close of business on November 12.

16:05 EDT IntriCon CFO Ellen Scipta steps down - Intricon announced that Ellen Scipta has stepped down from her position as Chief Financial Officer, effective October 29, 2021. Annalee Lutgen, current Treasurer and Director of Finance, will serve as interim Chief Financial Officer effective upon Ms. Scipta's resignation as the company conducts its search for a permanent replacement.

15:17 EDT Khosla Ventures Acquisition Co. II to transfer listing to NYSE from Nasdaq - Khosla Ventures Acquisition Co. II announced that it will voluntarily transfer the listing of its Class A common stock from the Nasdaq Capital Market to the New York Stock Exchange in connection with, and upon the closing of, the previously announced business combination with Nextdoor. The shares of Class A common stock of the post-business combination company, to be renamed Nextdoor Holdings, will trade under the stock symbol "KIND". KVSB's Class A common stock will continue to trade on the Nasdaq until the closing of the Business Combination. In compliance with Nasdaq's Listing Rules, KVSB provided Nasdaq with notice of its intent to delist its Class A common stock from Nasdaq after market close on November 5. The NYSE listing and Nasdaq delisting are subject to the closing of the Business Combination and fulfillment of all NYSE listing requirements.

15:15 EDT Entergy raises quarterly dividend 6c to $1.01 per share - Entergy Corporation has declared a quarterly dividend payment on its common stock of $1.01, an increase of 6c per share. The dividend is payable Dec. 1 to shareholders of record as of Nov. 15.

15:12 EDT FDA approves Pfizer, BioNTech Covid vaccine for ages 5-11

13:37 EDT Novartis' NDA for Scemblix approved by FDA - Scemblix is a kinase inhibitor indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML, in chronic phase, previously treated with two or more tyrosine kinase inhibitors, according to a post to the FDA website. "This indication is approved under accelerated approval based on major molecular response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)," the prescribing information states. Scemblix is also indicated for the treatment of adult patients with the Ph+ CML in CP with the T315I mutation, the FDA cites shows. Reference Link

13:03 EDT Baker Hughes reports U.S rig count up two from last week to 544 - Baker Hughes reports the U.S. rig count is up two from last week to 544 with oil rigs up one to 444, gas rigs up one to 100, and miscellaneous rigs unchanged at 0. U.S. Rig Count is up 248 rigs from last year's count of 296, with oil rigs up 221 gas rigs up 28 and miscellaneous rigs down three. The U.S. offshore rig count is unchanged at 13, unchanged year-over-year.

12:32 EDT Wolters Kluwer acquires U.S. business licensing services provider LicenseLogix - Wolters Kluwer Governance, Risk & Compliance has acquired LicenseLogix, a provider of U.S. business licensing services, the company announced. "This is an exciting and strategic acquisition for us. As the demand for business license services increases, the acquisition of LicenseLogix cements our position as a leader in this market. In addition to the strategic fit, we have worked with LicenseLogix for several years and have the highest respect for David Yount and the whole LicenseLogix team," said John Weber, President and CEO of Wolters Kluwer CT Corporation. "The company has been a strategic partner of GRC's CT Corporation for over five years and today serves more than 800 corporate customers of all sizes and across all industries," the company noted.

12:00 EDT Rafael Holdings falls -14.6% - Rafael Holdings is down -14.6%, or -$1.19 to $6.91.

12:00 EDT Onion Global falls -35.6% - Onion Global is down -35.6%, or -$3.21 to $5.80.

12:00 EDT Retail Value rises 23.6% - Retail Value is up 23.6%, or $1.21 to $6.33.

11:43 EDT Skylight Health enters agreement to divest legacy business to New Frontier Data - Skylight Health Group announced the execution of a Definitive Agreement with New Frontier Data to divest 100% of assets related to its legacy businesses Canna Care Docs and Relaxed Clarity. The legacy business was engaged in clinical evaluations and recommendations for patients seeking medical cannabis for state regulated conditions. New Frontier Data will be purchasing 100% of the Legacy Business for a total cash consideration of $8,628,000; Cannabis patients will continue to receive services under the new management; Skylight will utilize cash proceeds from the sale to purchase additional primary care practices; and This divesture allows Skylight to now focus fully on the traditional healthcare market and support of value-based primary care models. Terms of the transaction will be a total cash consideration of $8,628,000. Payment terms will include cash on closing of $4,000,000, with the remainder of the balance paid over three installments at 12 months, 18 months and 24 months from the date of closing. Skylight expects to use the cash proceeds to further acquire primary care practices in its pipeline. The transaction is expected to close no later than November 30, 2021, subject to customary closing conditions, exchange approval and board approvals.

11:19 EDT Microsoft acquires Two Hat, terms not disclosed - Microsoft announced that it has acquired Two Hat, a content moderation solution provider offering protection measures for online communities with a vision to build better experiences for everyone. "Globally, growing amounts of harmful content shared online have increased the need for effective and proactive content moderation," said Dave McCarthy, corporate vice president at Microsoft's Xbox Product Services. "For any online community to thrive, content moderation is a critical investment to ensure positive user experiences and maintain engagement over time. Microsoft and Two Hat share a vision for using advancements in moderation technology to nurture and protect diverse, global online communities." Terms of the transaction were not disclosed.

11:09 EDT Amazon discloses 20% stake in electric vehicle marker Rivian - Amazon.com disclosed in its quarterly filing that its preferred stock of Rivian Automotive represents an approximately 20% ownership interest, carrying a value of $3.8B as of September 30, 2021. Rivian on October 1 filed documents for an initial public offering on the Nasdaq under the symbol "RIVN." The company designs, develops and manufactures electric vehicles and accessories. As of September 30, it had approximately 48,390 R1T and R1S preorders in the United States and Canada from customers who each paid a cancellable and fully refundable deposit of $1,000.

10:17 EDT Moderna announces agreement with Gavi to supply up 116.5M COVAX doses - Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up 116.5M doses of Moderna's COVID-19 vaccine to be delivered in the second quarter of 2022. "The exercise of these options for additional doses represents an increase from an earlier agreement for 60 million doses of Moderna's COVID-19 vaccine that was communicated earlier this year. As per the advance purchase agreement signed on behalf of the COVAX Facility, Gavi continues to retain the option to procure 233 million additional doses in 2022 for a potential total of 500 million doses between 2021 and 2022 under the agreement. All doses are offered at Moderna's lowest tiered price, in line with the Company's global access commitments. This agreement covers the 92 Gavi COVAX Advance Market Commitment (low- and middle-income countries. COVAX is a global initiative co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels," the company stated.

10:00 EDT Havertys falls -15.1% - Havertys is down -15.1%, or -$4.86 to $27.38.

10:00 EDT Onion Global falls -31.1% - Onion Global is down -31.1%, or -$2.80 to $6.21.

10:00 EDT Retail Value rises 25.8% - Retail Value is up 25.8%, or $1.32 to $6.44.

09:49 EDT Starbucks CEO says looking at options related to unionization decision - Starbucks CEO Kevin Johnson said he doesn't think it is in "partners best interest" to put a third-party between the company and employees and that the company is looking at its options related to the NLRB labor board decision. Johnson made the comments while being interviewed on CNBC.

09:47 EDT Zendesk falls -21.6% - Zendesk is down -21.6%, or -$25.65 to $93.36.

09:47 EDT Santander Mexico rises 11.3% - Santander Mexico is up 11.3%, or 65c to $6.40.

09:47 EDT Retail Value rises 32.0% - Retail Value is up 32.0%, or $1.64 to $6.76.

09:46 EDT Starbucks CEO says 'going deeper and broader' in China - Starbucks CEO Kevin Johnson says accelerated in September in terms of same-store sales growth in both China and U.S. Johnson is being interview on CNBC.

09:36 EDT Exxon Mobil increases Q4 dividend to 88c per share - Exxon Mobil in its earnings release said it expects "to be well within debt-to-capital target range by year end" and that its Q4 dividend is increased to 88c per share.

09:32 EDT Air Canada enacts Return to the Workplace Plan - Air Canada said that it has enacted a Return to the Workplace Plan to transition employees working remotely safely back into the workplace, beginning November 15. The plan, developed in compliance with Public Health Agency of Canada guidelines, uses a hybrid approach combining on-site and remote work options to give employees flexibility and confidence as they return to their pre-pandemic work routines. Beginning November 15, those Air Canada employees who are presently working off-site will start a graduated return to the workplace, with options to continue working set days remotely. To ensure the health and safety of employees in the workplace: A mandatory vaccination policy requires all active employees to be fully vaccinated; All visitors and anyone entering company buildings are required to be fully vaccinated; Employees will be strongly encouraged to wear a face mask whenever outside of their personal workspaces or when interacting with others; Physical distancing is required where practical; Home screening programs continue to be offered and their use encouraged; Hand sanitizer and disinfection products will continue to be readily available.

09:12 EDT MusclePharm appoints Jason May to MP beverage team - MusclePharm Corporation announced a partnership with former Rockstar Energy executive, Jason May. May will join the MP beverage team currently headed up by Joey Cannata, another Rockstar Energy veteran. The MP beverage team will be launching two fully functional energy drink lines, MP Combat Energy and FitMiss Energy, and Mr. May will be responsible for building out the national marketing strategy for both lines. MP Combat Energy will launch in the fall of 2021 in three flavors: Grapefruit Lime, Green Apple and Black Cherry and FitMiss Energy will launch in early 2022, also with three flavors.

09:08 EDT Wrap receives largest single international order - Wrap Technologies announced that the Company received a new repeat order from an International distributor for 500 BolaWrap 100 devices, 50,000 cartridges, and related accessories. WRAP received the order in late October and the revenue is expected to be recognized in Q4 2021 and Q1 2022. The BolaWrap has already been shipped to 50 countries.

09:06 EDT Chicken Soup for the Soul relaunches Popcornflix AVOD network - Chicken Soup for the Soul Entertainment announced the re-launch of its action-film-focused Popcornflix's, AVOD with a new user experience. The newly relaunched platform features updated branding and offers a better user experience with enhanced app features, new search functionality and navigation scheme; server-side ad insertion; and improved playback performance putting the content in the hands of fans instantly.The relaunch also includes updated Popcornflix VOD apps, which are now available on the web as well as Apple TV, Fire TV, Android mobile, Android TV, iOS, Samsung, LG, Chromecast and Roku. Popcornflix FAST channel and VOD offerings are also available on PLEX and Redbox, with upcoming launches on PHILO, fuboTV, FreeCast, and Xumo.

09:04 EDT Comstock Holding, ParkX Management announce four new parking facilities - Comstock and ParkX Management, a commercial garage management subsidiary, announce the addition of four new parking facilities with over 2,500 public spaces in Maryland and Virginia. The new locations serve multiple office, residential, retail, mixed-use and hotel spaces in Park Potomac, Rockville Town Center, and Reston Station.

09:02 EDT Dr. Reddy's launches Ephedrine Sulfate Injection in U.S. - Dr. Reddy's announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz Injection, 50 mg/mL approved by the FDA.

08:51 EDT Nano-X Imaging enters agreement to deploy 350 Nanox systems in South America - Nano-X Imaging entered into an agreement with International Clinics Group, a medical equipment distributor which serves public & private hospitals, health systems, military hospitals, and medical centers in Chile, Bolivia and Peru. Subject to regulatory approval Nanox and International Clinics Group will deploy the Nanox System and auxiliary cloud services in both private and public healthcare facilities, to improve the availability of medical imaging for the overall population of Chile, Bolivia and Peru.

08:39 EDT Phunware accepting bitcoin for Lyte personal computers - Phunware announced it now accepts bitcoin for purchases of high performance computers and peripherals provided by its Lyte Technology business unit. To commemorate Phunware's acquisition of Lyte, Phunware has also launched Black Friday specials on four optimized personal computers designed specifically for crypto miners, gamers, streamers and traders.

08:36 EDT Helbiz to deploy fleet of e-scooters in Sacramento - Helbiz announced that it will deploy a fleet of 250 e-scooters in Sacramento, California after securing a one year permit. Helbiz will also open a local office and warehouse to run its operations on the ground, employing a full-time team to ensure its fleet is charged, repaired and well-maintained.

08:35 EDT American Water to sell Homeowner Services Group to Apax for $1.28B - American Water announced that it has agreed to sell its Homeowner Services Group to funds advised by Apax in a deal valued at approximately $1.28B. Upon closing of the transaction, American Water will receive $480M in cash and a $720M secured seller's Note bearing a 7% annual interest rate with a five-year term. In addition, the transaction includes a delayed payment to American Water of $75M if certain milestones are met by December 31, 2023. The structure of the transaction enables initial cash proceeds to be redeployed into the regulated water and wastewater business to fund near-term incremental capital investments, while interest on the seller's note will provide a stream of earnings over the term of the note. Upon maturity, the proceeds from the repayment of the Seller's Note are expected to be used to fund a continually growing capital investment in the regulated business. Homeowner Services Group's customer facing brands include American Water Resources and Pivotal Home Solutions, which provide various warranty protection programs and other home services to residential customers across the country. This business currently has nearly 3M customer contracts across 43 states and Washington, D.C. American Water will also enter into a revenue sharing agreement that provides for American Water to receive a percentage of revenue generated from previous on-bill billing arrangements with American Water customers. This agreement will also provide an ongoing income stream as Apax continues these relationships. American Water anticipates closing the transaction in Q4, subject to the satisfaction or waiver of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

08:33 EDT WWE announces preliminary court approval of shareholder derivative settlement - WWE announced the proposed settlement of certain shareholder derivative and other actions, filed August 17, has received preliminary court approval. The proposed settlement includes no financial obligation on the part of the company. The attached summary notice constitutes a required notice of the proposed settlement.

08:32 EDT Cushman & Wakefield announces $150M investment in WeWork - Cushman & Wakefield (CWK) announced the firm made a strategic investment of $150M on October 20 in WeWork (WE). As part of its strategic investment, Cushman & Wakefield's chief onvestment officer and EVP of strategic planning, Nathaniel Robinson, will serve as an observer to WeWork's board of directors. The two companies recently announced an exclusive strategic partnership intended to provide clients with office operations by combining WeWork's hospitality and technology-enabled services with Cushman & Wakefield's asset and facilities management services.

08:26 EDT GrowLife issues letter to shareholders on MyFungi, shareholder meeting - GrowLife released a letter to shareholders from the Chief Executive Officer of the Company Marco Hegyi. The letter said, "As we just announced, GrowLife has officially entered into an exclusive distribution agreement with My Fungi... Our exclusive agreement enables us to be the only supplier of these unique supplies throughout the United States. This is a milestone event for GrowLife, as we expand our focus beyond servicing cultivators in the cannabis industry into a new direction of being the leader in supporting mushroom cultivation... In the past few years, demand for mushrooms has skyrocketed across the board from use in nutraceuticals and plant-based wellness products, to specialty mushrooms used in foods, all the way to medicinal psychedelic mushrooms such as psilocybin.... While announcing this new direction for the Company may feel uneasy, I must reiterate that it aligns extremely well with GrowLife's core competency and existing sales and distribution channels. Most of the equipment for mushroom cultivation is being sold through hydroponics stores and online retailers, both of whom GrowLife has worked with for over a decade. Being the picks and shovels supplier to this burgeoning industry is both a strategic and complementary approach for our Company...One of the first steps in our strategic plan is the holding of a shareholder meeting. At this meeting we plan to put forward and seek approval on several items... We are seeking the support of our almost 100,000 shareholders who I hope can share in the excitement I have for this new direction and support our agenda. As I have said, a vote FOR is a vote FOR progress, and I believe that to be truer than ever, and the best way to unlock eventual shareholder value."

08:21 EDT Staffing 360 Solutions announces $9.25M private placement - Staffing 360 Solutions announced that it has entered into a securities purchase agreement with several institutional investors to purchase 4,683,547 shares of common stock in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investors unregistered warrants to purchase up to an aggregate of 4,683,547 shares of common stock. The purchase price for one share of common stock and one warrant to purchase one share of common stock is $1.975. The warrants have an exercise price of $1.85 per share, will be immediately exercisable, and will expire five years from issuance. The gross proceeds from the private placement are expected to be approximately $9.25 million. The offering is expected to close on or about November 2, 2021, subject to satisfaction of customary closing conditions. Staffing 360 intends to use the net proceeds received from the offering for repayment of debt and general working capital purposes. Assuming the closing of the private placement, the Company estimates that it will have approximately $9,356,000 of debt, as compared with approximately $55,369,000 as of January 2, 2021, representing a significant reduction of approximately 83%.

08:20 EDT Biomerica launches website for Aware breast exam device - Biomerica announced that in conjunction with Breast Cancer Awareness month, which takes place each October, it has launched its new website for the Aware at-home breast self-exam pad. Breast cancer is the most commonly-diagnosed cancer in women. In 2021, an estimated 281,550 new cases of invasive breast cancer will be diagnosed and approximately 43,600 women will die from breast cancer in US. One in eight women will develop invasive breast cancer in their lifetime. The Aware Breast exam pad is an FDA-cleared device. The product increases sensitivity in breast self-exams, making a self-exam easy and convenient.

08:16 EDT Immutep receives EMA scientific advice for further clinical development of efti - Immutep announces it has received positive feedback from the European Medicines Agency, EMA, regarding its clinical development program for lead product candidate, eftilagimod alpha, or efti, including the planned Phase III trial in MBC. In its scientific advice the EMA has supported the Company's view to continue the development of efti in MBC in a Phase III clinical trial, based on clinical data presented in December 2020 at SABCS. The trial will be built on the Company's ongoing Phase IIb AIPAC trial, which reported encouraging interim results in key patient subgroup populations. Final overall survival data from the Phase IIb AIPAC trial will be reported in mid November at SITC 2021 as a late breaker poster presentation. As the planned Phase III trial is intended to take place across multiple countries, additional interactions with the EMA and other regulators, including with the US FDA to generate a final study design are ongoing. Immutep CEO, Marc Voigt, noted: "Receiving positive and constructive EMA advice on our clinical development program for efti, including the planned Phase III trial in metastatic breast cancer is an exciting achievement for Immutep. We now look forward to further engagement with the EMA and other regulators, including the US FDA to solidify our trial plans."

08:14 EDT Sunrun announces program with SPAN to accelerate whole-home electrification - Sunrun announced that it has expanded its program with SPAN, the company that reinvented the electrical panel so homeowners can control and automate their energy consumption, to accelerate the transition away from fossil fuels and remove barriers for customers who want to electrify their homes and vehicles. Through the program, Sunrun is including SPAN home electrical panels as part of their home solar and battery offerings in select markets to drastically reduce installation hurdles when adopting on-site generation and other all-electric appliances. Combined with Sunrun's offering, SPAN smart home electrical panels enable customers to improve the energy resiliency of their home with solar energy, create fully customizable backup power switches, better manage home electrification upgrades, gain circuit-level visibility, and support the grid. Product pricing will vary according to market and installation requirements. "Widespread home electrification is vital to achieving our decarbonization goals but required main panel upgrades are often a significant hurdle for customers wanting to shift away from fossil fuels to clean-energy-powered alternatives in their homes," said Mary Powell, CEO of Sunrun. "This program will accelerate the adoption of home solar and batteries, electric vehicles, heat pumps, and so much more. SPAN's home electrical panel, with its intuitive app interface for homeowners, will reduce costs and installation complexities while providing improvements to Sunrun's customer experience through improved visibility and automation of our customers' energy needs."

08:13 EDT Royal Caribbean sees $600M in capital expenditures for remainder of 2021 - Royal Caribbean said: "Based upon current ship orders and delivery schedules, the projected capital expenditures for the remainder of 2021 are $600 million. The company expects the delivery of Silver Dawn to the Silversea fleet during the fourth quarter, which has committed financing. Depreciation and amortization expenses for the fourth quarter of 2021 are expected to be in the range of $325-330M. In 2022, the company has two ship deliveries scheduled, both with committed financing: Wonder of the Seas and Celebrity Beyond."

08:12 EDT Royal Caribbean CFO says demand 'surging back' as COVID cases have come down - "As cases have come down, demand has come surging back. Consumers are showing their resilience and desire to vacation, and the growing affinity of Royal Caribbean's leading brands, ships and crew. Although there are many uncertainties going forward regarding COVID-19, as well as cost and supply chain pressures,we continue our pathway forwardandanticipate positivecash flowfor the Group byspring of 2022and generatingpositive earningsfor the full year 2022," said Jason Liberty, Executive Vice President and CFO.

08:11 EDT Herman Miller announces Nasdaq ticker symbol change to 'MLKN' - Herman Miller will change its ticker symbol on the Nasdaq Stock Exchange from "MLHR" to "MLKN" at the open of market trading on Monday, November 1. This follows approval of the company's name change at the annual shareholder meeting on October 11. The company will also officially change its name from Herman Miller to MillerKnoll on November 1. The name change follows Herman Miller's acquisition of Knoll on July 19.

08:09 EDT Shell Midstream reports $1.2B in available liquidity - The Partnership anticipates repairs to WD-143 to be completed around mid-November 2021 with volumes then beginning to return to the Mars pipeline system. With this updated schedule, the Partnership now expects an impact of approximately $10-$15 million to both net income and cash available for distribution in the fourth quarter of 2021. The Partnership has approximately $1.2 billion in available liquidity, which is a combination of cash and cash equivalents and availability under credit facilities.

08:06 EDT HomeStreet expands share repurchase program up to $20M - HomeStree announced that the board of directors has approved an expansion of its share repurchase program, subject to the approval or nonobjection of its regulators. The approved expansion of the share repurchase program allows for the additional repurchase of up to $20M in aggregate amount of shares of the company's common stock.

08:04 EDT Yum! Brands' KFC U.S. names Nick Chavez as Chief Marketing Officer - Yum! Brands subsidiary KFC has named Nick Chavez Chief Marketing Officer of KFC U.S., effective November 29. Chavez has spent more than 11 years with Nintendo of America. Before joining NOA, Chavez spent over nine years at Yahoo! Inc., holding various marketing leadership roles, including Vice President of Brand Marketing.

08:04 EDT Arbor Realty raises quarterly dividend to 36c per share - The Company announced that its Board of Directors has declared a quarterly cash dividend of $0.36 per share of common stock for the quarter ended September 30, 2021, the Company's sixth consecutive quarterly increase, representing a 20% increase over that time span. The dividend is payable on November 30, 2021 to common stockholders of record on November 15, 2021. The ex-dividend date is November 12, 2021.

07:52 EDT AbbVie's cariprazine met primary endpoint in Phase 3 study - AbbVie announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine as an adjunctive treatment for patients with major depressive disorder. In Study 3111-301-001, cariprazine showed a statistically significant change from baseline to week six in the Montgomery-Asberg Depression Rating Scale total score compared with placebo. Patients treated with cariprazine at 1.5 mg/day achieved improved MADRS total score at week six compared to placebo. Patients treated with cariprazine at 3.0 mg/day demonstrated improvement in MADRS total score at week six over placebo but did not meet statistical significance. In Study 3111-302-001, cariprazine demonstrated numerical improvement in depressive symptoms from baseline to week six in MADRS total score compared with placebo but did not meet its primary endpoint for either the 1.5 mg/day or 3.0 mg/day dose. In a previously published Phase 2/3 registration-enabling study, RGH-MD-75, patients treated with cariprazine flexible doses of 2.0-4.5 mg/day in addition to ongoing antidepressant therapy met the primary endpoint and achieved improved MADRS total scores at week eight compared to placebo. Based on the positive results of studies 3111-301-001 and RGH-MD-75, and the totality of data reported, AbbVie intends to submit a supplemental New Drug Application with the U.S. FDA for the expanded use of cariprazine for the adjunctive treatment of MDD.

07:46 EDT AbbVie reports Q3 Global Humira sales of $5.425B up 5.6% on reported basis - In Q3: Global net revenues from the immunology portfolio were $6.674 billion, an increase of 15.3 percent on a reported basis, or 14.9 percent on an operational basis. Global Humira net revenues of $5.425 billion increased 5.6 percent on a reported basis, or 5.2 percent on an operational basis. U.S. Humira net revenues were $4.613 billion, an increase of 10.1 percent. Internationally, Humira net revenues were $812 million, a decrease of 14.6 percent on a reported basis, or 16.7 percent on an operational basis, due to biosimilar competition. Global Skyrizi net revenues were $796 million. Global Rinvoq net revenues were $453 million.

07:44 EDT AbbVie raises quarterly cash dividend to $1.41 from $1.30 per share - Beginning with the dividend payable on February 15, 2022 to shareholders of record as of January 14, 2022. This reflects an increase of approximately 8.5%, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend.

07:41 EDT Cytokinetics announces preclinical data on CK-3828136 - Cytokinetics announced that preclinical data relating to the discovery and optimization of CK-3828136 were presented at the 2021 Medicinal Chemistry Gordon Research Conference in West Dover, VT. CK-136 is a novel, selective cardiac troponin activator in development for the potential treatment of diseases associated with impaired cardiac contractility, such as heart failure with reduced ejection fraction (HFrEF), right ventricular heart failure, and others. Data presented describe the primary research objectives related to CK-136 including the identification of initial hit compounds and subsequent chemical optimization as well as preclinical characterization in biochemical assays, cardiac myocytes, and in vivo models of cardiac function. An initial cardiac troponin activator identified in screening was shown in a reconstituted sarcomere assay to selectively activate the cardiac troponin complex. Importantly, it did not inhibit phosphodiesterase 3 IC50, and showed no effect on the cardiomyocyte calcium transient, indicating its selectivity. The optimization of the initial hit compound that led to CK-136 focused to maximizing the therapeutic window and its pharmacokinetic profile as could result in favorable increases in cardiac function. Preclinical studies demonstrated that the pharmacodynamic range for CK-136 was larger than that associated with omecamtiv mecarbil in similar preclinical models. Additionally, CK-136 demonstrated a pharmacokinetic profile and a projected human half-life that should enable once or twice daily dosing. These preclinical data suggest that CK-136 is a selective cardiac troponin activator with a favorable pharmacodynamic window associated with substantial increases in cardiac contractility, representing a potential approach to augmenting cardiac contractility in diseases characterized by reduced cardiac function.

07:39 EDT Jushi Holdings opens 26th BEYOND / HELLO retail location - Jushi Holdings announced the opening of its 26th retail location nationwide and the second of six dispensary openings in Virginia for the Company, through its subsidiary Dalitso LLC. On Tuesday, November 2nd at 10:00 a.m., BEYOND / HELLO Sterling will begin serving Virginia medical cannabis patients and registered agents, providing an unparalleled customer-centric retail experience, coupled with online ordering through beyond-hello.com and convenient in-store express pickup. On Tuesday, November 2nd, Jushi's newest Northern Virginia dispensary will also begin serving medical cannabis patients through the Company's delivery program to meet the rising demand and improve patient accessibility.

07:37 EDT Pipestone Energy announces upsized credit facility of $280M - Pipestone Energy announced that it has increased its Reserve Based Loan to $280 million, from $225 million previously. The Credit Facility upsize is driven by Pipestone's efficient execution of its organic development program, resulting in a significant increase to its proved producing reserve value during 2021. The larger credit capacity provides Pipestone with increased liquidity and flexibility with respect to its go-forward business plans and future shareholder return objectives. Pipestone Energy has closed on its bi-annual RBL redetermination, which effective October 29, 2021, consists of a $250 million syndicated revolving facility and a $30 million bi-lateral operating facility. Co-led by National Bank Financial Inc., and the Bank of Montreal, and along with ATB Financial, and Canadian Western Bank the corporate banking syndicate has been expanded to also include the Business Development Bank of Canada. Additionally, Pipestone has amended its credit agreement to allow for future permitted distributions, subject to certain customary liquidity and forecast leverage tests. The Credit Facility continues to have a revolving period until May 31, 2022, with a maturity of May 31, 2023. The next borrowing base redetermination is scheduled for May 2022.

07:34 EDT Gilead announces interim results from BICSTaR study - Gilead announced interim results from the ongoing, multinational, observational single-arm, non-comparative real-world cohort BICSTaR study, which is designed to evaluate the antiviral effectiveness and safety profile of Biktarvy in 1,135 people living with HIV. The BICSTaR study also collected patient-reported outcomes in routine clinical practice to better understand the impact of treatment on health-related quality of life in people living with HIV. These data were presented at the 18th European AIDS Conference. Gilead presented an analysis of patient-reported outcomes after 12 months of treatment with Biktarvy from the BICSTaR study. During the study, conducted at sites in Europe, Canada and Israel, people living with HIV who initiated treatment with Biktarvy between June 2018 and September 2020 completed questionnaires at baseline and 12 months. The questionnaires assessed patient-reported outcomes covering a range of measures. The results underline the importance of collecting patient-reported outcomes in order to understand the impact on mental health status, health-related quality of life and treatment satisfaction of people living with HIV. In a second analysis of the BICSTaR study, 97% of treatment-naive adults and 96% of treatment-experienced adults achieved and maintained virologic suppression after one year of treatment. Participants included adults 50 years of age or older, cisgender women, and late presenters. Both treatment-naive and treatment-experienced participants had high persistence with Biktarvy across both groups, Biktarvy was generally well-tolerated and no resistance to the components of Biktarvy emerged. 148 participants had any adverse event and two had a serious adverse event. The most common drug-related adverse events observed to date in the BICSTaR study were weight increase, nausea, depression, headache, fatigue, diarrhoea and sleep disorder. These large cohort findings continue to reinforce the real-world effectiveness of Biktarvy across populations and are consistent with evidence from randomized clinical trials. Additional Biktarvy data presented at EACS 2021 include a Phase 3 trial that demonstrated the durable efficacy of Biktarvy. In the study, 99% of people living with HIV who switched to Biktarvy from a boosted protease inhibitor-based regimen maintained and achieved long-term viral suppression through a median of 101 weeks, including 98% of participants with pre-existing resistance and 98% of participants with viral blips, with no treatment-emergent resistance to Biktarvy. A pooled analysis of five Phase 3 studies also found that regardless of pre-existing TAMS, a high proportion of those on Biktarvy were able to maintain virologic suppression and had an absence of treatment-emergent resistance. These data support the continued evaluation of Biktarvy as a potential option for virologically suppressed people living with HIV with known resistance. The use of Biktarvy in individuals with a history of treatment failure or known resistance to the components of Biktarvy is investigational, and the safety and efficacy of Biktarvy for this use have not been established.

07:30 EDT Oramed's oral COVID-19 vaccine approved for Phase 1 trial in South Africa - Oramed's majority-owned subsidiary, Oravax Medical, has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its oral COVID-19 vaccine and preparations to begin the trials are now underway. Oravax's virus-like particle vaccine technology targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the COVID-19 virus.

07:17 EDT NFI Group's ADL invited by UK government to show electric double-deck buses - NFI Group announced that its subsidiary Alexander Dennis Limited is showcasing one of its electric, zero-emission, double-deck buses at the 26th United Nations Climate Change Conference of the Parties in Glasgow, Scotland. The bus, a BYD ADL Enviro400EV double decker that has been kindly lent by bus operator National Express from its West Midlands fleet, is located inside the security-controlled Blue Zone, where negotiations between world leaders take place. ADL was invited by the UK Government as organisers of COP26 to present its solutions for sustainable transport to negotiators and global leaders in the Blue Zone at COP26. Over 1,000 battery-electric buses built in Britain by ADL in partnership with BYD are already on the road or on order in the United Kingdom, and second-generation hydrogen buses will follow next year.

07:16 EDT Novavax files for provisional approval of its COVID-19 vaccine in Australia - Novavax announced the completion of its rolling submission to the Therapeutic Goods Administration for provisional approval of its COVID-19 vaccine candidate. The company's application to the TGA marks the first complete application for provisional approval of a protein-based COVID-19 vaccine in Australia.

07:14 EDT Glatfelter completes acquisition of Jacob Holm - Glatfelter Corporation announced it has completed the previously disclosed acquisition of Jacob Holm for aggregate consideration of approximately $302 million including the extinguishment of Jacob Holm's existing debt and other adjustments. This transaction was funded through a new $500 million senior unsecured notes issuance. The addition of Jacob Holm will meaningfully increase Glatfelter's scale and diversification into attractive and complementary product categories with high-performing and innovative spunlace nonwoven technologies and advanced plant-based sustainable solutions serving the growing wipes, critical cleaning, healthcare and hygiene categories. Glatfelter has acquired four additional manufacturing sites, one converting operation, and six sales offices located in the Americas, Europe, and Asia, and approximately 760 employees worldwide. Jacob Holm generated $401 million of net sales and $42.5 million of adjusted EBITDA for the twelve-month period ended June 30, 2021. Glatfelter believes these results included a benefit from COVID-related demand estimated to be between $10 million and $15 million of adjusted EBITDA. This acquisition is expected to yield approximately $20 million of annual synergies within 24 months.

07:12 EDT Athira Pharma to host educational webinar on clinical applications of ERP P300 - Athira Pharma announced it will host an educational webinar to review event-related potential P300 latency as a functional measure of working memory processing speed, and its correlation to cognition. The webinar will be webcast live on Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET, and will feature presentations by: J ohn Michael Olichney, M.D., a board-certified behavioral neurologist who specializes in the treatment of cognitive disorders and age-associated neurodegenerative diseases. Dr. Olichney is Professor of Neurology at UC Davis Health. Kevin Church, Ph.D., Vice President of Discovery at Athira. Dr. Church will introduce the unique mechanism of ATH-1017, a small molecule therapeutic candidate designed to enhance the activity of HGF/MET, discuss the rationale for ERP P300 latency measurements and preclinical ATH-1017 data generated to date. Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira. Dr. Moebius will review Athira's clinical development program and discuss the utility of ERP P300 latency in Athira's completed Phase 1 and ongoing Phase 2 ACT-AD trial of ATH-1017. Athira is measuring ERP P300 latency in a clinical trial of its investigational drug, ATH-1017, for the treatment of mild-to-moderate Alzheimer's disease to evaluate a connection between this functional measurement and improved cognition. The ACT-AD clinical study completed enrollment in October 2021 and topline data from the study is expected to be announced in the first half of 2022.

07:10 EDT Canaan receives follow.on order from Hive Blockchain for 6,500 bitcoin machines - Canaan (CAN) has secured a follow-on purchase order from Hive Blockchain (HIVE) for 6,500 units of its next-generation Avalon Bitcoin mining machines. This new order by Hive follows the two recent purchases of 4,000 units and 6,400 units of Canaan's Avalon Miners in August 2021 and January 2021, respectively.

07:07 EDT PLx Pharma provides launch update on launch of Vazalore - PLx Pharma provided a Vazalore launch update, including the following: supplied three stock keeping units of Vazalore into more than 30,000 retail drugstores, supermarkets, mass merchandisers nationwide, and e-commerce sites; launched a national media television campaign targeting providers and consumers; received positive feedback from consumers and healthcare professionals; major retailers have begun to place Vazalore in multiple locations within stores; and aspirin remains an established foundational therapy in practice guidelines for prevention of another heart attack or clot-related stroke. The company's launch strategy for Vazalore targets the over 40 million patients at risk of having another heart attack or stroke, and diabetics who are at high risk for having such an event and thus may be candidates for aspirin therapy under the guidance of their physician.

07:03 EDT Charter reports Q3 free cash flow of $2.5B, up 41.2% y/y

06:58 EDT Colgate-Palmolive: Difficult cost environment to continue for next few quarters - Noel Wallace, Chairman, President and CEO, commented on the third quarter results, "We are pleased to have delivered another quarter of organic sales growth at the high end of our targeted range of 3% to 5% despite a difficult comparison in the year ago period and the impact of restricted mobility and supply chain disruptions due to COVID-19. Net sales increased 6.5% and organic sales grew 4.5% driven by both volume growth and higher pricing. Net income and earnings per share both increased on a Base Business basis, despite significant increases in raw material and logistics costs. We expect the difficult cost environment to continue for the next several quarters and we remain sharply focused on our funding the growth and revenue growth management initiatives, including additional pricing. We are encouraged by our performance this quarter, but as we look around the world, there is still much uncertainty stemming from the COVID-19 pandemic, supply chain disruptions and volatility in consumer demand and currencies. In this difficult environment, we remain committed to executing our plans with focus and agility and believe we have the right strategies in place to continue to deliver sustainable, profitable growth over the long term."

06:51 EDT Roche says IMPACT trial shows 'clear benefit' of CINtec PLUS Cytology test - Roche announced that results from the IMPACT - IMproving Primary screening And Colposcopy Triage - trial demonstrate clear patient benefit in using Roche's CINtec PLUS Cytology dual-stain biomarker technology as a triage test for women who test positive for high-risk human papillomavirus, or HPV. The data from the trial, established from a study cohort of more than 35,000 women aged 25-65 years, was published recently in the International Journal of Cancer. In the IMPACT trial, women who were positive for high-risk HPV received a follow-up triage test to help determine if their cervical cells were transforming to cervical pre-cancer. The biomarker-based CINtec PLUS Cytology test showed a significantly higher sensitivity in detecting cervical pre-cancers, compared to Pap cytology. The Roche test aids clinicians in more confidently determining which women are at increased risk for high-grade cervical pre-cancer and require immediate further diagnostic procedures, and which women may need repeat testing or routine screening. In the study, HPV-positive women with CINtec PLUS Cytology negative triage test results showed a very low cumulative 1-year risk for disease, which was significantly lower than the risks associated with a negative Pap cytology triage test result in HPV-positive women. Based on the results of the IMPACT trial, the FDA approved the CINtec PLUS Cytology test to be used as triage for positive HPV test results using cobas HPV on cobas 4800, 6800 and 8800 Systems in primary screening or co-testing programs. Recommended clinical guidelines have also been evolving in favor of HPV tests for primary screening, supported by an interest to improve outcomes and the availability of technologies to help laboratories achieve the efficiency and scale they need to meet the demands of high-volume cervical screening programs.

06:43 EDT AdvanSix expects CapEx $63M in 2021 - Continues to expect $95M-$105M in 2022 reflecting scope of planned plant turnarounds and timing of project execution Expects pre-tax income impact of planned plant turnarounds to be approximately $30M in 2021. "The outlook for our business remains favorable. We are building off a strong foundation with leading positions across our key product lines aligned to a diverse and growing set of end uses and applications. Our enhanced capital allocation strategy, including the recent initiation of a quarterly dividend, is creating further shareholder value over the long-term. We've demonstrated our ability to successfully perform through all market conditions and expand our earnings base and are even more excited about the opportunities that lie ahead for AdvanSix," said CEO Kane.

06:39 EDT inTEST acquires Videology Imaging Solutions for $12M in cash - inTEST announced it has acquired substantially all of the assets of Videology Imaging Solutions Inc. and Videology Imaging Solutions Europe B.V., a global designer, developer and manufacturer of OEM digital streaming and image capturing solutions. inTEST acquired the assets of Videology for total consideration of $12M in cash. Videology's trailing twelve month revenue as of the end of September 2021 was approximately $10M and provided comparable gross margins with inTEST. The company expects the acquisition to be approximately 5c accretive to diluted earnings per share in its first year with inTEST, net of one-time acquisition related expenses. inTEST expects acquisition related expenses to be approximately 3c per diluted share in the fourth quarter of 2021.

06:36 EDT Hormel Foods CFO Jim Sheehan to retire, Jacinth Smiley to succeed - Hormel Foods announced that Jim Sheehan plans to retire as executive vice president and CFO after 43 years with the company. Jacinth Smiley, group vice president of corporate strategy, has been named his successor and will become the company's next executive vice president and CFO, reporting to Jim Snee, chairman of the board, president and chief executive officer. Sheehan's career at Hormel Foods spans more than four decades, including the last five years as chief financial officer for the company's global operations. Sheehan plans to retire at the end of the calendar year. Smiley, who will succeed Sheehan upon his retirement, joined Hormel Foods in 2021 as group vice president of corporate strategy after two decades in financial and accounting.

06:35 EDT L3Harris Technologies CEO views pandemic-related impacts as 'temporary' - "The L3Harris team delivered solid bookings, margins, and bottom-line results in the quarter, overcoming revenue headwinds due to supply chain delays and award timing. And in spite of unprecedented global supply chain disruptions that are reducing our organic revenue growth guidance for the year, we're positioned to meet our earnings and cash flow commitments," said Christopher Kubasik, Vice Chair and CEO. "We ultimately view these pandemic-related impacts as temporary and remain focused on creating value for our stakeholders over the long term."

06:21 EDT EssilorLuxottica now sees mid to high single digit revenue growth for FY21 - In light of the sound performance of the third quarter, EssilorLuxottica has upgraded its full year 2021 guidance, which now points to mid-to-high single digit growth in revenue versus 2019 at constant exchange rates from mid single digit, and an up-to-100 basis points progress in adjusted operating profit as a percentage of revenue compared to 2019 at constant exchange rates, from just "higher than 2019."

06:17 EDT Gorman-Rupp hikes quarterly dividend 9.7%, announces $50M share repurchase plan - The Board of Directors of The Gorman-Rupp Company has declared a quarterly cash dividend of 17c per share on the common shares of the company, payable December 10 to shareholders of record November 15. The cash dividend will represent a 9.7% increase over the 15.5c dividend per share paid in the previous quarter. This is the 49th consecutive year of increased dividends, which positions Gorman-Rupp in the top 50 of all U.S. public companies with respect to number of years of increased dividend payments. In addition, the company announced that its Board of Directors has authorized a share repurchase program of up to $50M of the company's common stock. The authorization does not have an expiration date.

06:11 EDT Ares Management awarded project with Community of Madrid for affordable housing - Ares Management announced that funds managed by the Ares Real Estate Group were awarded a public-private partnership with the Community of Madrid to develop more than 3,600 affordable rental residential units in Madrid. As part of its Plan VIVE, the Community of Madrid has awarded Ares a 50-year concession to invest EUR400M in developing housing across 13 municipalities in Madrid. Ares has committed to developing this portfolio within three years and to cap the rent per unit at a material discount to current market rent, providing important affordable housing for lower- and middle-income residents. Avalon Properties, an asset manager majority-owned by Ares, will oversee the assets as part of Ares' Madrid rental residential strategy. Ares has partnered with Madrid-based companies AEDAS Homes, a leading residential developer in Spain, and Grupo SANJOSE, a global construction company, to act as the project manager and developer, and constructor, respectively. Plan VIVE establishes a novel partnership between the Community of Madrid, Ares, AEDAS Homes and Grupo SANJOSE intended to help address the affordable housing shortage for lower- and middle-income communities.

06:09 EDT Arbitrators find Albemarle defrauded Huntsman in 2014 sale of pigments business - On October 28, a panel of three former federal judges sitting as arbitrators found that Albemarle (ALB) had defrauded Huntsman (HUN) in connection with the sale of its pigments business in 2014, breached the contract under which the business was sold, and awarded Huntsman in excess of $600M for the fraud and breach, inclusive of punitive damages and statutory interest at 9% of which the company expects to net in excess of $400M after attorney's fees. The award is subject to confirmation and limited appeal in the New York state court.

06:01 EDT Chevron reports Q3 cash flow from operations $8.6B, free cash flow $6.7B

05:20 EDT Walmart enters exclusive agreement with RevolutionParts for OEM auto parts - RevolutionParts and Walmart announced an exclusive agreement to bring OEM automotive parts to the Walmart Marketplace. As part of the relationship, Walmart will build out pages dedicated to OEM parts, making the parts easier to find. Customers will be able to search for parts based on the make, model and year of their vehicle.

05:11 EDT Sportradar receives IBIA Data Standards Kitemark accreditation - Sportradar announced that it has been granted the International Betting Integrity Association's, or IBIA, Data Standards Kitemark, one of the industry's accreditation related to the quality assurance processes related to the collection of data for the purposes of sports betting.